Australian Trefoil Health Technologies Pty Ltd, established in 2015, is a high-tech innovative biotechnology enterprise headquartered in Lane Cove West Business Park, Sydney, Australia. Strategically located adjacent to the renowned North Ryde Business Park—often referred to as Sydney's "Silicon Valley"—the company benefits from proximity to leading global organizations, including Microsoft, Cisco, the Australian Institute of Life Sciences, and Macquarie University.
Founded by two distinguished scientists—Dr. Horace Drew, a former CSIRO researcher with a PhD from Caltech, and Dr. Jianguo Yang, widely recognized as the "father of selenoprotein P"—the company is guided by the core philosophy that "technology is productivity, and innovation is competitiveness."
Trefoil is dedicated to addressing major health challenges facing humanity through an integrated model that spans basic research, applied research, product development, core technology services, and manufacturing. The company's multidisciplinary research team comprises top experts in medicine, biochemistry, genetic engineering, food science, and pharmaceuticals. By translating cutting-edge scientific discoveries into practical solutions, Trefoil serves as a vital bridge in Australia's and the global "big health" industry ecosystem.
The company operates three state-of-the-art laboratories specializing in genetics, biochemistry, and microbiology, enabling comprehensive R&D from foundational studies to applied innovations. Since inception, Trefoil has secured three independent Australian patents, with four additional patent applications currently under review. It has obtained TGA approval for one product (DNA Repair) and has several others in the registration pipeline.
During the 2020 COVID-19 pandemic, Trefoil played a proactive role in public health response by contributing to the development of diagnostic solutions. It was among the earliest Australian manufacturers to achieve TGA emergency authorization for a COVID-19 antibody rapid test kit and PCR detection kit, demonstrating agility and commitment to addressing urgent global health needs.
In recent years, the company has strategically shifted focus toward anti-aging and human degenerative disease research and product development. Leveraging deep collaborations with universities and research institutions worldwide, Trefoil has expanded its portfolio to encompass two major categories—specialized nutrition and functional nutrition—featuring over ten innovative products.
To foster international scientific exchange and advance nutritional health innovation, the company has organized and hosted the International Nutrition and Health Forum in multiple locations: Haikou, China (December 2023), Shenyang, China (May 2024), and Macau (June 2025).
With scientific research as its guiding principle, innovation as its core driver, and high-quality products as its foundation, Australian Trefoil Health Technologies Pty Ltd is committed to establishing a prominent and influential position in both the Australian domestic and global health industries.
